Company Category: Research Institute

The Division of Pulmonary, Sleep Medicine and Cystic Fibrosis at Nationwide Children’s Hospital provides the highest quality clinical care for children and adults with congenital respiratory disorders, including cystic fibrosis, advanced lung disease, sleep-related breathing disorders and more. Our providers care for patients approaching and following lung/heart-lung transplant and those managing long-term mechanical ventilation. We are proud of the care we provide to children with respiratory disease, and this was acknowledged again this year by U.S. News & World Report as we have remained a top 10 pediatric pulmonary department since 2012! | At Nationwide Children’s Hospital, we understand the importance of translating innovative work beyond our walls and into the world. New technologies drive economic development in our local, national, and global ecosystem and most importantly, improve pediatric care. The Office of Technology Commercialization exists to ensure that the necessary partnerships are in place to execute this important function. Nationwide Children’s Hospital is one of America’s largest pediatric hospitals, an international leader in research, and is ranked in all 10 specialties on U.S. News & World Report’s 2023-24 “America’s Best Children’s Hospitals” list. In addition, according to the Children’s Hospital Association, Nationwide Children’s is the #1 provider of pediatric surgery in the country. The Abigail Wexner Research Institute at Nationwide Children’s Hospital has earned its reputation as an institution with a remarkable track record of moving discoveries into the marketplace. The hospital’s innovators, stationed in more than 800,000 square feet of dedicated research space, are committed to enhancing the health of children by engaging in high-quality, cutting-edge research according to the highest scientific and ethical standards while advancing life-saving therapies to children everywhere. The Office of Technology Commercialization at Nationwide Children’s guides ideas to solutions by offering expertise in technology transfer and facilitating partnerships between inventors and industry to bring discoveries to patients, clinicians and scientists around the world. Our resourceful team guides Nationwide Children’s clinicians, researchers, and partners through complex processes with creative solutions. This ranges from therapeutics, biomarkers, diagnostic tools, research and clinical tools, and medical devices. Some of our successes include first-of-their-kind gene therapies, Zolgensma and Elevidys – FDA-approved treatments for Spinal Muscular Atrophy (SMA) and Duchenne Muscular Dystrophy (DMD) – and medical devices like the Comfort Collar or the Endoscopic Retrieval Device. Nationwide Children’s Hospital, located in Columbus, Ohio and with over 16,000 employees, is leading a bold journey to best outcomes for children everywhere. | The Nationwide Children’s Hospital Office of Technology Commercialization (OTC) guides ideas to solutions by offering expertise in technology transfer and facilitating partnerships between inventors and industry to bring discoveries to patients, clinicians and scientists around the world. Our resourceful team guides inventors and partners through complex processes with creative solutions. This ranges from therapeutics, including the approved, first-of-their-kind gene therapies – Zolgensma and Elevidys, FDA-approved treatments for Spinal Muscular Atrophy (SMA) and Duchenne Muscular Dystrophy (DMD) – to biomarkers, diagnostic tools and clinical tools – such as the Comfort Collar, designed to prevent pressure wounds around tracheostomy tubes – to outside partners to benefit patients, the local community and the general public. As a result, the Abigail Wexner Research Institute at Nationwide Children’s Hospital has earned its reputation as an institution with a remarkable track record of moving discoveries into the marketplace. The hospital’s physicians and researchers are dedicated to enhancing the health of children by engaging in high-quality, cutting-edge research according to the highest scientific and ethical standards while advancing life-saving therapies to children everywhere. We encourage all interested entrepreneurs and potential licensing partners to stop by the Ohio Pavilion (Booth No. 1865) to discuss our many available preclinical and clinical technologies, ranging from early-stage innovations to market-ready products. Our portfolio of over 200 available technologies developed by our innovative researchers and clinicians at Nationwide Children’s Hospital is diverse and ever-growing. | The Office of Technology Commercialization (OTC) at Nationwide Children’s Hospital supports the translation of innovative research into real-world healthcare solutions. Working closely with clinicians, researchers, and industry partners, OTC advances intellectual property development, licensing, and startup formation to bring pediatric-focused technologies to market. OTC also collaborates closely with the Nationwide Children’s Innovation Center to foster cross-disciplinary innovation and accelerate the development of novel solutions from concept through commercialization. Nationwide Children’s Hospital is consistently ranked among the top 10 children’s hospitals in the nation by U.S. News & World Report, earning the “Honor Roll” distinction for 12 consecutive years as of 2025. It is also the #1 ranked pediatric hospital in Ohio and the Midwest and is consistently among the top NIH-funded pediatric research institutions in the United States, reflecting its national leadership in biomedical discovery and translational science. Together, Nationwide Children’s, the OTC and Innovation Center drive collaboration and commercialization efforts that accelerate the development of life-changing therapies, devices, and diagnostics for children worldwide.